Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1726 to 1740 of 7682 results

  1. TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation (MT512)

      Status ...

  2. Bladder EpiCheck for the detection of bladder cancer recurrence (MT706)

      Status ...

  3. Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy TS ID 10214

    Awaiting development [GID-TA11069] Expected publication date: TBC

  4. Mavorixafor for treating WHIM syndrome ID3946

    Awaiting development [GID-TA10833] Expected publication date: TBC

  5. Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

    Awaiting development [GID-QS10106] Expected publication date: TBC

  6. Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]

    Awaiting development [GID-TA10843] Expected publication date: TBC

  7. Safeguarding adults in care homes

    Awaiting development [GID-QS10147] Expected publication date: TBC

  8. Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]

    Awaiting development [GID-TA10773] Expected publication date: TBC

  9. Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]

    Awaiting development [GID-TA10867] Expected publication date: TBC

  10. Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]

    Awaiting development [GID-TA10683] Expected publication date: TBC

  11. Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]

    Awaiting development [GID-TA10869] Expected publication date: TBC

  12. Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]

    Awaiting development [GID-TA10896] Expected publication date: TBC

  13. Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]

    Awaiting development [GID-TA10916] Expected publication date: TBC

  14. Bupivacaine–meloxicam for treating postoperative pain [ID2728]

    Awaiting development [GID-TA10716] Expected publication date: TBC

  15. Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297

    In development [GID-TA10311] Expected publication date: TBC